Research Alert: CFRA Keeps Buy View On Shares Of Alnylam Pharmaceuticals, Inc.

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We cut our target to $165 from $188 on o

MT Newswires05:20

Earnings Call Summary | Alnylam Pharmaceuticals(ALNY.US) Q1 2024 Earnings Conference

The following is a summary of the Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript:Financial Performance:Alnylam Pharmaceuticals reported Q1 2024 product revenue of $365 million,

Futu News03:08 · Conference Call

Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $200 Price Target

Needham analyst Joseph Stringer reiterates Alnylam Pharmaceuticals with a Buy and maintains $200 price target.

Analyst Upgrades02:41

Needham: Reiterates Alnylam Pharmaceuticals (ALNY.US) rating and adjusted from buy to buy rating, target price is $200.00.

Needham: Reiterates Alnylam Pharmaceuticals (ALNY.US) rating and adjusted from buy to buy rating, target price is $200.00.

Zhitong Finance02:40

Alnylam Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 32.63% Needham → $200 Reiterates Buy → Buy 03/27/2024 55.17% BMO Capital $234 → $234 Maintains

Benzinga02:39

Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript

Earnings Call Transcripts00:15